No Data
No Data
No Data
No Data
No Data
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Susquehanna
BenzingaApr 22 08:32 ET
Express News | Chardan Capital Maintains Buy on Ocugen, Raises Price Target to $5
Moomoo 24/7Apr 22 07:47 ET
Ocugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 267.65% Chardan Capital $4 → $5 Maintains Buy 04/03/2024 414.71% HC Wainwright & Co. → $7 Reite
BenzingaApr 22 07:44 ET
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration
Ocugen (OCGN) said Friday it has completed dosing in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA), a modifier gene therapy to treat age-related macular degeneration.
MT NewswiresApr 19 08:19 ET
Express News | Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 Armada Clinical Trial of Ocu410—a Modifier Gene Therapy
Moomoo 24/7Apr 19 07:13 ET
Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a
OcugenApr 19 00:00 ET
No Data
No Data